Method of efficiently establishing induced pluripotent stem cells
The present invention provides a method of improving the efficiency of establishment of induced pluripotent stem (iPS) cells, comprising inhibiting the p53 function in the step of somatic cell nuclear reprogramming. The inhibition of p53 function is achieved by bringing a substance selected from the group consisting of (1) chemical inhibitors of p53, (2) dominant negative mutants of p53 and nucleic acids that encode the same, (3) siRNAs and shRNAs against p53 and DNAs that encode the same, and (4) p53 pathway inhibitors, into contact with a somatic cell, and the like. The present invention also provides an agent for improving the efficiency of establishment of iPS cells, the agent comprising an inhibitor of p53 function, particularly (1) chemical inhibitors of p53, (2) dominant negative mutants of p53 and nucleic acids that encode the same, (3) siRNAs and shRNAs against p53 and DNAs that encode the same, and (4) p53 pathway inhibitors. The present invention further provides a method of producing an iPS cell, comprising bringing a nuclear reprogramming substance and an inhibitor of p53 function into contact with a somatic cell.
1. An in vitro method of improving the efficiency of establishment of an induced pluripotent stem (iPS) cell, comprising contacting an isolated somatic cell being reprogrammed into an iPS cell with siRNA or shRNA that inhibits p53 or DNA that encodes the siRNA or shRNA.
2. The method of claim 1 , wherein the isolated somatic cell being reprogrammed into an iPS cell is contacted with siRNA that inhibits p53 or DNA that encodes the siRNA.
3. The method of claim 1 , wherein the isolated somatic cell being reprogrammed into an iPS cell is contacted with shRNA that inhibits p53 or DNA that encodes the shRNA.
4. An in vitro method of producing iPS cells, comprising bringing (a) nuclear reprogramming substances or nucleic acids encoding the nuclear reprogramming substances and (b) an inhibitor of p53 function into contact with a somatic cell, wherein the nuclear reprogramming substances are (i) Oct3/4 and Klf4, (ii) Oct3/4 and c-Myc, (iii) Oct3/4, Klf4 and Sox2, (iv) Oct3/4, Klf4 and c-Myc, or (v) Oct3/4, Klf4, Sox2 and c-Myc, and wherein the inhibitor of p53 function is siRNA or shRNA that inhibits p53 or DNA that encodes the siRNA or shRNA.
5. The method of claim 4 , wherein the nuclear reprogramming substances are Oct3/4, Klf4 and Sox2, or nucleic acids that encode the same.
6. The method of claim 4 , wherein the nuclear reprogramming substances are Oct3/4, Klf4, Sox2 and c-Myc, or nucleic acids that encode the same.
7. The method of claim 4 , wherein the somatic cell is a T cell.
8. The method of claim 4 , wherein the inhibitor of p53 function is siRNA that inhibits p53 or DNA that encodes the siRNA.
9. The method of claim 7 , wherein the inhibitor of p53 function is shRNA that inhibits p53 or DNA that encodes the shRNA.